Needham analyst Mike Matson downgrades NeoGenomics (NASDAQ:NEO) from Buy to Hold.
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Alpine Immune Sciences Inc (NASDAQ:ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and…